Over the next few years, the most successful organizations will be those that use the current opportunity to rethink their MI workflows and develop hybrid human-AI models.

Lifesciences firms need to invest in technology that unifies data and workflows across medical information teams and safety teams. Integrating MI and safety helps them optimize the drug development lifecycle and ultimately drive greater patient safety.

An effective medical affairs and medical information strategy includes evidence and insights generation, data dissemination/scientific exchange, customer engagement, and a digital and innovation roadmap.